evoke semaglutide Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Results of EVOKE and EVOKE+

Patients with inflammatory bowel conditions, leaky gut, or NSAID-induced gastric damage have sought it as an adjunct or alternative therapy

Preliminary data shows GLP-1 therapy doesnt lead to more lean mass loss than other weight-loss methods, especially when paired with exercise and nutrition support

Peer review Peer review information Nature Communications thanks Hongli Mao, and the other, anonymous, reviewer for their contribution to the peer review of this work

375,376 Retrieval to the ER for ERAD requires substrate recognition by retention in endoplasmic reticulum sorting receptor 1 (Rer1) 377 or surfeit locus protein 4 (Surf4), 378,379 both of which reside in the cis-Golgi

However, the behaviors were weaker among GLP-1 users